Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Insulin Resistance | 56 | 2024 | 637 | 7.990 |
Why?
|
Diabetes Mellitus, Type 2 | 61 | 2024 | 1269 | 7.960 |
Why?
|
Blood Glucose | 39 | 2024 | 1138 | 3.690 |
Why?
|
Insulin | 39 | 2024 | 1202 | 3.300 |
Why?
|
Obesity | 35 | 2024 | 2262 | 3.190 |
Why?
|
Overweight | 13 | 2024 | 363 | 2.670 |
Why?
|
Insulin-Secreting Cells | 18 | 2020 | 149 | 2.420 |
Why?
|
Pediatric Obesity | 11 | 2022 | 383 | 2.380 |
Why?
|
Prediabetic State | 10 | 2024 | 57 | 2.380 |
Why?
|
Adiposity | 10 | 2023 | 190 | 2.350 |
Why?
|
Metformin | 15 | 2024 | 151 | 2.030 |
Why?
|
Diabetes Mellitus, Type 1 | 13 | 2023 | 818 | 2.020 |
Why?
|
Body Mass Index | 23 | 2024 | 1561 | 1.900 |
Why?
|
Hypoglycemic Agents | 13 | 2024 | 442 | 1.820 |
Why?
|
Adolescent | 94 | 2024 | 19280 | 1.790 |
Why?
|
Glucose Tolerance Test | 19 | 2020 | 208 | 1.570 |
Why?
|
Body Composition | 15 | 2024 | 522 | 1.440 |
Why?
|
Cardiorespiratory Fitness | 2 | 2022 | 10 | 1.330 |
Why?
|
Adipose Tissue | 13 | 2021 | 462 | 1.330 |
Why?
|
Basal Metabolism | 2 | 2024 | 95 | 1.090 |
Why?
|
Vascular Stiffness | 5 | 2022 | 73 | 1.070 |
Why?
|
Glucose | 7 | 2023 | 880 | 1.030 |
Why?
|
Metabolic Syndrome | 7 | 2021 | 338 | 1.030 |
Why?
|
Child | 68 | 2024 | 24375 | 1.030 |
Why?
|
Glucose Clamp Technique | 18 | 2021 | 76 | 1.010 |
Why?
|
Hyperglycemia | 4 | 2023 | 222 | 0.970 |
Why?
|
Endothelium, Vascular | 3 | 2019 | 520 | 0.970 |
Why?
|
Calorimetry | 1 | 2024 | 61 | 0.940 |
Why?
|
Glucose Intolerance | 8 | 2018 | 78 | 0.930 |
Why?
|
Male | 84 | 2024 | 61192 | 0.870 |
Why?
|
C-Peptide | 9 | 2021 | 113 | 0.870 |
Why?
|
Female | 87 | 2024 | 66485 | 0.870 |
Why?
|
Humans | 111 | 2024 | 124596 | 0.860 |
Why?
|
Biomarkers | 13 | 2024 | 3063 | 0.810 |
Why?
|
Glucagon-Like Peptide-1 Receptor | 2 | 2020 | 62 | 0.800 |
Why?
|
Obesity, Abdominal | 2 | 2012 | 37 | 0.790 |
Why?
|
Cardiovascular Diseases | 9 | 2020 | 1947 | 0.790 |
Why?
|
Energy Metabolism | 2 | 2024 | 775 | 0.780 |
Why?
|
Vitamin D | 3 | 2019 | 161 | 0.770 |
Why?
|
Bariatric Surgery | 1 | 2023 | 119 | 0.770 |
Why?
|
Vitamin D Deficiency | 3 | 2019 | 73 | 0.760 |
Why?
|
Obesity, Morbid | 1 | 2023 | 187 | 0.730 |
Why?
|
Albuminuria | 2 | 2023 | 99 | 0.680 |
Why?
|
Non-alcoholic Fatty Liver Disease | 2 | 2023 | 395 | 0.670 |
Why?
|
Cross-Sectional Studies | 11 | 2024 | 3424 | 0.670 |
Why?
|
Atherosclerosis | 3 | 2016 | 914 | 0.660 |
Why?
|
Biomarkers, Pharmacological | 1 | 2019 | 10 | 0.660 |
Why?
|
Registries | 7 | 2020 | 1424 | 0.650 |
Why?
|
Liraglutide | 1 | 2019 | 14 | 0.650 |
Why?
|
Models, Biological | 1 | 2024 | 1459 | 0.650 |
Why?
|
Drug Approval | 1 | 2019 | 42 | 0.640 |
Why?
|
Kidney Diseases | 1 | 2023 | 480 | 0.610 |
Why?
|
Abdominal Fat | 8 | 2012 | 19 | 0.590 |
Why?
|
Young Adult | 24 | 2024 | 9014 | 0.570 |
Why?
|
Health Status Disparities | 2 | 2016 | 227 | 0.550 |
Why?
|
Adiponectin | 8 | 2019 | 113 | 0.540 |
Why?
|
Polycystic Ovary Syndrome | 2 | 2018 | 58 | 0.540 |
Why?
|
Sleep | 4 | 2024 | 344 | 0.520 |
Why?
|
Endothelium | 1 | 2016 | 70 | 0.520 |
Why?
|
Pericardium | 1 | 2016 | 81 | 0.520 |
Why?
|
Risk Factors | 24 | 2024 | 10270 | 0.510 |
Why?
|
Pulse Wave Analysis | 6 | 2023 | 46 | 0.490 |
Why?
|
Heart Ventricles | 3 | 2018 | 762 | 0.480 |
Why?
|
Peptide Hormones | 2 | 2006 | 68 | 0.470 |
Why?
|
Hyperinsulinism | 4 | 2013 | 67 | 0.470 |
Why?
|
Maternal Nutritional Physiological Phenomena | 1 | 2015 | 48 | 0.460 |
Why?
|
Ventricular Function, Left | 2 | 2018 | 506 | 0.440 |
Why?
|
Incretins | 4 | 2019 | 24 | 0.430 |
Why?
|
Fetal Development | 1 | 2015 | 132 | 0.430 |
Why?
|
Intercellular Signaling Peptides and Proteins | 3 | 2005 | 279 | 0.430 |
Why?
|
Creatinine | 1 | 2015 | 390 | 0.430 |
Why?
|
Calcinosis | 1 | 2014 | 176 | 0.420 |
Why?
|
Puberty | 2 | 2024 | 94 | 0.410 |
Why?
|
Body Weight | 4 | 2016 | 996 | 0.390 |
Why?
|
Autoantibodies | 6 | 2021 | 434 | 0.390 |
Why?
|
Absorptiometry, Photon | 7 | 2022 | 177 | 0.390 |
Why?
|
Resistance Training | 1 | 2012 | 32 | 0.390 |
Why?
|
Exercise | 2 | 2020 | 813 | 0.380 |
Why?
|
Cohort Studies | 10 | 2024 | 4795 | 0.370 |
Why?
|
Prenatal Exposure Delayed Effects | 1 | 2013 | 225 | 0.350 |
Why?
|
Triglycerides | 4 | 2023 | 575 | 0.350 |
Why?
|
Amino Acids | 3 | 2024 | 664 | 0.350 |
Why?
|
Fatty Acids, Nonesterified | 2 | 2021 | 136 | 0.340 |
Why?
|
Diabetic Angiopathies | 4 | 2020 | 65 | 0.330 |
Why?
|
Diabetic Neuropathies | 1 | 2020 | 58 | 0.320 |
Why?
|
Lipid Metabolism | 1 | 2012 | 356 | 0.320 |
Why?
|
Lipolysis | 2 | 2021 | 79 | 0.320 |
Why?
|
Adult | 18 | 2024 | 29438 | 0.310 |
Why?
|
Fasting | 7 | 2020 | 298 | 0.300 |
Why?
|
Coronary Artery Disease | 1 | 2014 | 772 | 0.290 |
Why?
|
Thiazoles | 2 | 2016 | 98 | 0.280 |
Why?
|
Peptide YY | 1 | 2006 | 19 | 0.260 |
Why?
|
Dyslipidemias | 5 | 2021 | 232 | 0.260 |
Why?
|
Longitudinal Studies | 3 | 2023 | 1322 | 0.250 |
Why?
|
Heart Rate | 3 | 2023 | 590 | 0.240 |
Why?
|
Carotid Intima-Media Thickness | 2 | 2016 | 74 | 0.240 |
Why?
|
Intra-Abdominal Fat | 2 | 2021 | 51 | 0.240 |
Why?
|
Liver | 1 | 2012 | 1739 | 0.240 |
Why?
|
Prognosis | 4 | 2023 | 4626 | 0.240 |
Why?
|
Circadian Rhythm | 2 | 2024 | 272 | 0.230 |
Why?
|
Fluoxetine | 1 | 2024 | 43 | 0.230 |
Why?
|
Diabetes Complications | 3 | 2024 | 201 | 0.230 |
Why?
|
Prehypertension | 2 | 2016 | 11 | 0.230 |
Why?
|
Sertraline | 1 | 2024 | 44 | 0.230 |
Why?
|
Human Growth Hormone | 1 | 2024 | 74 | 0.230 |
Why?
|
Prospective Studies | 4 | 2023 | 6135 | 0.220 |
Why?
|
Amino Acids, Branched-Chain | 1 | 2024 | 77 | 0.220 |
Why?
|
Child, Preschool | 4 | 2024 | 14009 | 0.220 |
Why?
|
Body Height | 1 | 2024 | 215 | 0.210 |
Why?
|
Alanine Transaminase | 1 | 2023 | 156 | 0.210 |
Why?
|
Prevalence | 8 | 2020 | 2445 | 0.210 |
Why?
|
Gene-Environment Interaction | 1 | 2023 | 121 | 0.210 |
Why?
|
Glutamic Acid | 1 | 2024 | 203 | 0.210 |
Why?
|
Glutamine | 1 | 2024 | 215 | 0.200 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2024 | 341 | 0.200 |
Why?
|
Glucagon-Like Peptide 1 | 2 | 2020 | 71 | 0.200 |
Why?
|
Glomerular Filtration Rate | 2 | 2023 | 503 | 0.200 |
Why?
|
Melatonin | 1 | 2022 | 25 | 0.200 |
Why?
|
United States | 10 | 2020 | 10887 | 0.200 |
Why?
|
Regression Analysis | 5 | 2006 | 778 | 0.190 |
Why?
|
Obesity, Metabolically Benign | 1 | 2021 | 3 | 0.190 |
Why?
|
Pennsylvania | 4 | 2017 | 53 | 0.190 |
Why?
|
Pasteurella Infections | 1 | 2001 | 7 | 0.180 |
Why?
|
Pasteurella multocida | 1 | 2001 | 8 | 0.180 |
Why?
|
Treatment Failure | 2 | 2019 | 337 | 0.180 |
Why?
|
Self Report | 1 | 2024 | 512 | 0.180 |
Why?
|
Practice Patterns, Physicians' | 2 | 2018 | 728 | 0.180 |
Why?
|
Muscular Dystrophies | 1 | 2001 | 52 | 0.180 |
Why?
|
Wearable Electronic Devices | 1 | 2022 | 105 | 0.170 |
Why?
|
C-Reactive Protein | 1 | 2023 | 428 | 0.170 |
Why?
|
Diastole | 2 | 2022 | 170 | 0.170 |
Why?
|
Hypoglycemia | 3 | 2018 | 191 | 0.170 |
Why?
|
Diabetic Nephropathies | 2 | 2020 | 107 | 0.170 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2023 | 681 | 0.170 |
Why?
|
Energy Intake | 1 | 2023 | 493 | 0.170 |
Why?
|
Bone Density | 1 | 2022 | 319 | 0.170 |
Why?
|
Oxidation-Reduction | 1 | 2021 | 440 | 0.170 |
Why?
|
Weight Loss | 1 | 2023 | 482 | 0.170 |
Why?
|
Vitamin D-Binding Protein | 1 | 2019 | 6 | 0.160 |
Why?
|
Autonomic Nervous System Diseases | 1 | 2019 | 43 | 0.160 |
Why?
|
Hyperemia | 1 | 2019 | 27 | 0.160 |
Why?
|
Minority Groups | 2 | 2018 | 247 | 0.160 |
Why?
|
Cell Adhesion Molecules | 1 | 2020 | 221 | 0.160 |
Why?
|
Ideal Body Weight | 1 | 2018 | 3 | 0.160 |
Why?
|
Nutrition Surveys | 2 | 2017 | 293 | 0.150 |
Why?
|
United States Food and Drug Administration | 1 | 2019 | 149 | 0.150 |
Why?
|
Proteins | 1 | 2004 | 1036 | 0.150 |
Why?
|
Follow-Up Studies | 7 | 2021 | 5145 | 0.150 |
Why?
|
Public Health | 1 | 2020 | 262 | 0.150 |
Why?
|
Risk | 2 | 2017 | 755 | 0.140 |
Why?
|
Viscera | 3 | 2008 | 55 | 0.140 |
Why?
|
Pneumonia | 1 | 2001 | 323 | 0.140 |
Why?
|
Texas | 2 | 2016 | 3583 | 0.140 |
Why?
|
Age of Onset | 4 | 2020 | 586 | 0.140 |
Why?
|
25-Hydroxyvitamin D 2 | 1 | 2016 | 6 | 0.140 |
Why?
|
Calcifediol | 1 | 2016 | 13 | 0.140 |
Why?
|
Reference Values | 3 | 2008 | 711 | 0.130 |
Why?
|
Genome-Wide Association Study | 1 | 2023 | 1684 | 0.130 |
Why?
|
Systole | 1 | 2016 | 198 | 0.130 |
Why?
|
Hypertension | 3 | 2021 | 1320 | 0.130 |
Why?
|
Pregnancy in Diabetics | 1 | 2015 | 19 | 0.130 |
Why?
|
Arrhythmias, Cardiac | 1 | 2019 | 460 | 0.120 |
Why?
|
Case-Control Studies | 3 | 2019 | 3281 | 0.120 |
Why?
|
Ghrelin | 2 | 2006 | 53 | 0.120 |
Why?
|
Blood Pressure | 5 | 2011 | 1352 | 0.120 |
Why?
|
Abnormalities, Multiple | 1 | 2001 | 959 | 0.120 |
Why?
|
Albumins | 1 | 2015 | 89 | 0.120 |
Why?
|
Seasons | 1 | 2016 | 310 | 0.120 |
Why?
|
Mass Screening | 2 | 2018 | 782 | 0.120 |
Why?
|
Patient Selection | 1 | 2018 | 693 | 0.120 |
Why?
|
Lipids | 1 | 2018 | 514 | 0.110 |
Why?
|
Diabetic Cardiomyopathies | 1 | 2014 | 16 | 0.110 |
Why?
|
Clinical Trials as Topic | 1 | 2018 | 1089 | 0.110 |
Why?
|
Pregnancy | 3 | 2015 | 7179 | 0.110 |
Why?
|
Pregnancy Outcome | 1 | 2015 | 588 | 0.100 |
Why?
|
Meals | 1 | 2013 | 57 | 0.100 |
Why?
|
Islets of Langerhans | 2 | 2021 | 174 | 0.100 |
Why?
|
Intention to Treat Analysis | 1 | 2012 | 64 | 0.100 |
Why?
|
Treatment Outcome | 4 | 2019 | 12322 | 0.100 |
Why?
|
Patient Dropouts | 1 | 2012 | 51 | 0.100 |
Why?
|
Chronic Disease | 1 | 2016 | 1185 | 0.100 |
Why?
|
Life Style | 3 | 2016 | 406 | 0.090 |
Why?
|
Heart Atria | 1 | 2014 | 316 | 0.090 |
Why?
|
Drug Combinations | 2 | 2016 | 267 | 0.090 |
Why?
|
Random Allocation | 1 | 2012 | 436 | 0.090 |
Why?
|
Fatty Liver | 1 | 2012 | 184 | 0.090 |
Why?
|
Adolescent Behavior | 1 | 2012 | 168 | 0.090 |
Why?
|
Child Behavior | 1 | 2012 | 230 | 0.090 |
Why?
|
Combined Modality Therapy | 3 | 2020 | 1231 | 0.090 |
Why?
|
Drug Therapy, Combination | 3 | 2020 | 1162 | 0.090 |
Why?
|
Aging | 1 | 2017 | 1182 | 0.090 |
Why?
|
Lipoproteins, HDL | 2 | 2006 | 100 | 0.080 |
Why?
|
Fatty Acids | 1 | 2012 | 346 | 0.080 |
Why?
|
Dehydroepiandrosterone Sulfate | 1 | 2008 | 19 | 0.080 |
Why?
|
Tomography, X-Ray Computed | 5 | 2011 | 2091 | 0.070 |
Why?
|
Testosterone | 1 | 2013 | 533 | 0.070 |
Why?
|
Abdomen | 1 | 2008 | 127 | 0.070 |
Why?
|
Comorbidity | 3 | 2018 | 1529 | 0.070 |
Why?
|
Disease Progression | 3 | 2018 | 2047 | 0.070 |
Why?
|
Depression | 1 | 2015 | 1218 | 0.070 |
Why?
|
Body Weights and Measures | 1 | 2006 | 42 | 0.070 |
Why?
|
Respiratory Physiological Phenomena | 1 | 2006 | 17 | 0.070 |
Why?
|
Cardiovascular Physiological Phenomena | 1 | 2006 | 29 | 0.070 |
Why?
|
Time Factors | 3 | 2024 | 6292 | 0.060 |
Why?
|
Physical Fitness | 1 | 2006 | 90 | 0.060 |
Why?
|
Estradiol | 1 | 2008 | 535 | 0.060 |
Why?
|
Waist-Hip Ratio | 1 | 2006 | 56 | 0.060 |
Why?
|
Muscle, Skeletal | 1 | 2012 | 947 | 0.060 |
Why?
|
Leptin | 2 | 2023 | 216 | 0.060 |
Why?
|
Phenotype | 3 | 2023 | 4256 | 0.060 |
Why?
|
Anthropometry | 1 | 2016 | 199 | 0.060 |
Why?
|
Pediatrics | 2 | 2018 | 1164 | 0.060 |
Why?
|
ROC Curve | 3 | 2015 | 569 | 0.060 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2023 | 2634 | 0.050 |
Why?
|
Sample Size | 1 | 2023 | 86 | 0.050 |
Why?
|
Diabetes Mellitus | 1 | 2012 | 871 | 0.050 |
Why?
|
Arteriosclerosis | 1 | 2003 | 144 | 0.050 |
Why?
|
Data Interpretation, Statistical | 1 | 2023 | 231 | 0.050 |
Why?
|
Severity of Illness Index | 3 | 2017 | 2891 | 0.050 |
Why?
|
Actigraphy | 1 | 2022 | 45 | 0.050 |
Why?
|
Light | 1 | 2022 | 176 | 0.050 |
Why?
|
Transcription Factor 7-Like 2 Protein | 1 | 2021 | 24 | 0.050 |
Why?
|
Ear | 1 | 2001 | 25 | 0.050 |
Why?
|
Hair | 1 | 2001 | 23 | 0.050 |
Why?
|
Mouth Abnormalities | 1 | 2001 | 15 | 0.050 |
Why?
|
Aging, Premature | 1 | 2001 | 30 | 0.050 |
Why?
|
Toes | 1 | 2001 | 28 | 0.050 |
Why?
|
Animals, Domestic | 1 | 2001 | 31 | 0.050 |
Why?
|
Models, Statistical | 1 | 2023 | 471 | 0.050 |
Why?
|
Reproducibility of Results | 1 | 2008 | 2876 | 0.040 |
Why?
|
Fingers | 1 | 2001 | 65 | 0.040 |
Why?
|
Life History Traits | 1 | 2020 | 5 | 0.040 |
Why?
|
Micrognathism | 1 | 2001 | 65 | 0.040 |
Why?
|
Behavioral Medicine | 1 | 2020 | 10 | 0.040 |
Why?
|
Magnetic Resonance Imaging | 1 | 2012 | 3552 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2024 | 1689 | 0.040 |
Why?
|
Nose | 1 | 2001 | 93 | 0.040 |
Why?
|
Echocardiography | 2 | 2018 | 1052 | 0.040 |
Why?
|
Saliva | 1 | 2001 | 114 | 0.040 |
Why?
|
Dogs | 1 | 2001 | 768 | 0.040 |
Why?
|
Middle Aged | 3 | 2020 | 26714 | 0.040 |
Why?
|
Evidence-Based Practice | 1 | 2020 | 112 | 0.040 |
Why?
|
Cleft Palate | 1 | 2001 | 140 | 0.040 |
Why?
|
Autonomic Nervous System | 1 | 2019 | 45 | 0.040 |
Why?
|
Risk Reduction Behavior | 1 | 2020 | 142 | 0.040 |
Why?
|
Retrospective Studies | 4 | 2021 | 16314 | 0.040 |
Why?
|
Gene Expression Regulation | 1 | 2007 | 2521 | 0.040 |
Why?
|
Syndrome | 1 | 2001 | 1119 | 0.040 |
Why?
|
Contraceptives, Oral, Hormonal | 1 | 2018 | 19 | 0.040 |
Why?
|
Adolescent Medicine | 1 | 2018 | 22 | 0.040 |
Why?
|
Diabetic Retinopathy | 1 | 2020 | 155 | 0.040 |
Why?
|
Diet Therapy | 1 | 2018 | 41 | 0.040 |
Why?
|
Proof of Concept Study | 1 | 2017 | 29 | 0.040 |
Why?
|
Thiazolidinediones | 1 | 2018 | 82 | 0.030 |
Why?
|
Animals | 2 | 2013 | 34072 | 0.030 |
Why?
|
Androgen Antagonists | 1 | 2018 | 119 | 0.030 |
Why?
|
Health Promotion | 1 | 2020 | 389 | 0.030 |
Why?
|
Morbidity | 1 | 2017 | 247 | 0.030 |
Why?
|
Gynecology | 1 | 2018 | 123 | 0.030 |
Why?
|
Gastric Inhibitory Polypeptide | 1 | 2016 | 19 | 0.030 |
Why?
|
Inflammation | 2 | 2018 | 1431 | 0.030 |
Why?
|
Exercise Therapy | 1 | 2018 | 153 | 0.030 |
Why?
|
Glucagon | 1 | 2016 | 185 | 0.030 |
Why?
|
Diabetic Ketoacidosis | 1 | 2018 | 160 | 0.030 |
Why?
|
Austria | 1 | 2015 | 19 | 0.030 |
Why?
|
Infant, Newborn | 2 | 2015 | 8190 | 0.030 |
Why?
|
Endocrinology | 1 | 2018 | 135 | 0.030 |
Why?
|
Germany | 1 | 2015 | 65 | 0.030 |
Why?
|
Medical Records | 1 | 2016 | 189 | 0.030 |
Why?
|
Stillbirth | 1 | 2015 | 80 | 0.030 |
Why?
|
Heart | 1 | 2019 | 708 | 0.030 |
Why?
|
E-Selectin | 1 | 2014 | 41 | 0.030 |
Why?
|
Socioeconomic Factors | 1 | 2018 | 866 | 0.030 |
Why?
|
Research Design | 1 | 2018 | 691 | 0.030 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 1 | 2014 | 62 | 0.030 |
Why?
|
Cholesterol, LDL | 1 | 2018 | 569 | 0.030 |
Why?
|
Academic Medical Centers | 1 | 2016 | 307 | 0.030 |
Why?
|
Intercellular Adhesion Molecule-1 | 1 | 2014 | 137 | 0.030 |
Why?
|
Ventricular Dysfunction | 1 | 2014 | 25 | 0.030 |
Why?
|
Age Factors | 1 | 2020 | 2818 | 0.030 |
Why?
|
Atrial Function, Left | 1 | 2014 | 27 | 0.030 |
Why?
|
Nutritional Status | 1 | 2015 | 314 | 0.030 |
Why?
|
Lipoproteins | 1 | 2014 | 179 | 0.030 |
Why?
|
Hypertrophy, Left Ventricular | 1 | 2014 | 109 | 0.030 |
Why?
|
Health Services Accessibility | 1 | 2018 | 606 | 0.030 |
Why?
|
Muscle, Smooth, Vascular | 1 | 2014 | 238 | 0.030 |
Why?
|
Delivery, Obstetric | 1 | 2015 | 251 | 0.030 |
Why?
|
Prenatal Care | 1 | 2015 | 347 | 0.030 |
Why?
|
Survival Rate | 1 | 2017 | 2044 | 0.030 |
Why?
|
Patient Compliance | 1 | 2015 | 471 | 0.020 |
Why?
|
Signal Transduction | 1 | 2024 | 4501 | 0.020 |
Why?
|
Gastrointestinal Diseases | 1 | 2015 | 336 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2015 | 1637 | 0.020 |
Why?
|
Carnitine | 1 | 2012 | 74 | 0.020 |
Why?
|
Linear Models | 1 | 2013 | 671 | 0.020 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2018 | 732 | 0.020 |
Why?
|
Glycemic Index | 1 | 2009 | 19 | 0.020 |
Why?
|
Immunoassay | 1 | 2009 | 130 | 0.020 |
Why?
|
Anti-Bacterial Agents | 1 | 2001 | 2426 | 0.020 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2008 | 342 | 0.020 |
Why?
|
Body Size | 1 | 2007 | 55 | 0.020 |
Why?
|
Predictive Value of Tests | 1 | 2012 | 2154 | 0.020 |
Why?
|
Hospitals, Pediatric | 1 | 2011 | 770 | 0.020 |
Why?
|
Proinsulin | 1 | 2006 | 12 | 0.020 |
Why?
|
Radiography, Abdominal | 1 | 2006 | 47 | 0.020 |
Why?
|
Infant | 1 | 2001 | 12469 | 0.020 |
Why?
|
Oxygen Consumption | 1 | 2006 | 305 | 0.020 |
Why?
|
Exercise Test | 1 | 2006 | 252 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2006 | 547 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2007 | 1882 | 0.010 |
Why?
|
Family | 1 | 2005 | 562 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2006 | 2050 | 0.010 |
Why?
|
Diet | 1 | 2005 | 1136 | 0.010 |
Why?
|